Trials / Unknown
UnknownNCT06184230
Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.
Open Label Study to Assess the ~32-Year Persistence of Hepatitis A Antibody Among Participants in the Pivotal, Double-Blind, Placebo-Controlled Efficacy Study of VAQTA (Study 023-001)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Best Healthcare Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the persistence of Hepatitis A antibody \~32 years post vaccination in healthy adults. The questions this study will answer are: 1) how long antibody persists and 2) The immune response to an additional dose of vaccine among those with no detectable antibody. Participants will be asked to provide a blood specimen. Those with no detectable antibody will be offered an additional dose of vaccine. The kinetics of antibody response in this population will be summarized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Hepatitis A Vaccine | Hepatitis A Vaccine |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2025-03-01
- Completion
- 2025-06-01
- First posted
- 2023-12-28
- Last updated
- 2023-12-28
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06184230. Inclusion in this directory is not an endorsement.